Voyager Therapeutics (VYGR) Net Margin (2015 - 2026)
Voyager Therapeutics (VYGR) posted Net Margin of 1077.4% for Q1 2026, down 503.95% sequentially from 178.39% in Q4 2025, and down 59816.0% YoY from N/an in Q1 2025.
Voyager Therapeutics (VYGR) Net Margin (2015 - 2026) Analysis & Trends
Voyager Therapeutics has reported Net Margin for 12 years, with the latest figure at 1077.4% in Q1 2026.
- Quarterly Net Margin fell 59816.0% year-over-year to 1077.4% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 319.27% (down 19283.0% YoY) and the FY2025 annual result came in at 296.53%, down 21528.0% from the prior year.
- Net Margin declined to 1077.4% in Q1 2026 per VYGR's latest filing, from 178.39% in the prior quarter.
- Over five years, Net Margin peaked at 1524.26% in Q4 2022 and troughed at 3239.97% in Q1 2022.
- A 5-year average of 499.13% and a median of 208.69% in 2025 frame the typical range for Net Margin.
- The sharpest annual moves came in 2022 and 2023: Net Margin tumbled 189616 bps in 2022, then soared 332240 bps in 2023.
- Over 5 years, Net Margin stood at 1524.26% in 2022, then slumped by 96 bps to 62.59% in 2023, then sank by 975 bps to 547.33% in 2024, then jumped by 67 bps to 178.39% in 2025, then sank by 504 bps to 1077.4% in 2026.
- According to Business Quant data, Net Margin over the past three periods registered 1077.4%, 178.39%, and 208.69% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 31.16% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -539.31% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 13.90% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 12.74% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -3.12% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 12.09% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -16.51% |
| 10 | Voyager Therapeutics | 201.32 Mn | 84.98 Mn | - | -764.78% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -764.78% |
| Mar 31, 2026 | -1,077.40% |
| Dec 31, 2025 | -178.39% |
| Sep 30, 2025 | -208.69% |
| Jun 30, 2025 | -641.96% |
| Mar 31, 2025 | -479.24% |
| Dec 31, 2024 | -547.33% |
| Sep 30, 2024 | -36.72% |
| Jun 30, 2024 | -34.29% |
| Mar 31, 2024 | -58.10% |
| Dec 31, 2023 | 62.59% |
| Sep 30, 2023 | -561.36% |
| Jun 30, 2023 | -453.22% |
| Mar 31, 2023 | 82.43% |
| Dec 31, 2022 | 1,524.26% |
| Sep 30, 2022 | 42.90% |
| Jun 30, 2022 | -2,680.76% |
| Mar 31, 2022 | -3,239.97% |
| Dec 31, 2021 | 20.34% |
| Sep 30, 2021 | -1,696.15% |